Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis
- PMID: 7848304
- DOI: 10.1002/art.1780380202
Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis
Abstract
This review has summarized information published over the last 5 years on the presence and pathophysiologic role of IL-1 and TNF alpha in RA. The evidence to date shows that 5 of 6 criteria for identifying mediators of tissue damage in human autoimmune diseases are satisfied (Table 1). The last criterion, prevention of clinical progression in patients with RA, is currently being evaluated. Many new therapeutic approaches are currently being developed, including the use of soluble receptors to IL-1 or TNF, monoclonal antibodies to TNF alpha, a specific IL-1 receptor antagonist, and gene therapy with the latter molecule. It should be emphasized that both IL-1 and TNF alpha play important roles in normal host defense; the possible complications of blocking their production or effects need to be carefully evaluated in long-term studies. A recent review has emphasized that although IL-1 and TNF alpha have many overlapping biologic properties, each may exhibit distinct effects in joint disease (99). Anti-TNF treatment may be primarily antiinflammatory but blocking IL-1 may be more effective in preventing cartilage destruction (100). The possibility exists that simultaneous inhibition of TNF alpha and IL-1 may be more therapeutically efficacious than blockade of either agent alone, as was recently demonstrated with IL-1ra and soluble TNF receptors in bacterial cell wall-induced arthritis in rats (101). The next level of clinical studies in rheumatoid arthritis should include the use of two biologic response modifiers together, or one agent combined with a more traditional form of therapy.
Similar articles
-
Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis.Cytokine. 1998 Sep;10(9):690-702. doi: 10.1006/cyto.1998.0372. Cytokine. 1998. PMID: 9770330
-
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.Arthritis Rheum. 2004 Jan;50(1):277-90. doi: 10.1002/art.11487. Arthritis Rheum. 2004. PMID: 14730626
-
IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.J Immunol. 1999 Nov 1;163(9):5049-55. J Immunol. 1999. PMID: 10528210
-
Biological response modifiers in the management of rheumatoid arthritis.Am J Health Syst Pharm. 2003 Feb 15;60(4):346-55. doi: 10.1093/ajhp/60.4.346. Am J Health Syst Pharm. 2003. PMID: 12625216 Review.
-
[New drugs and treatment strategies for rheumatoid arthritis].Recenti Prog Med. 2003 Sep;94(9):361-79. Recenti Prog Med. 2003. PMID: 12942798 Review. Italian.
Cited by
-
Relative expression and correlation of tumor necrosis factor-α, interferon-γ, and interleukin-17 in the rheumatoid synovium.Clin Rheumatol. 2016 Jul;35(7):1691-7. doi: 10.1007/s10067-016-3249-2. Epub 2016 Apr 1. Clin Rheumatol. 2016. PMID: 27038187
-
Effects of 18β-Glycyrrhetinic acid in hTNFtg mice - a model of rheumatoid arthritis.Wien Klin Wochenschr. 2012 Mar;124(5-6):170-6. doi: 10.1007/s00508-011-0103-z. Epub 2012 Jan 3. Wien Klin Wochenschr. 2012. PMID: 22210441
-
"In vitro" differences among (R) and (S) enantiomers of profens in their activities related to articular pathophysiology.Inflammation. 2005 Dec;29(4-6):119-28. doi: 10.1007/s10753-006-9003-1. Inflammation. 2005. PMID: 17089192
-
Osteoarthritis: can anti-cytokine therapy play a role in treatment?Clin Rheumatol. 2010 May;29(5):451-5. doi: 10.1007/s10067-009-1352-3. Epub 2010 Jan 27. Clin Rheumatol. 2010. PMID: 20108016 Review.
-
IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis.Arthritis Res. 2001;3(3):168-77. doi: 10.1186/ar294. Epub 2001 Jan 26. Arthritis Res. 2001. PMID: 11299057 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical